GlassScriptPhysician profile
Stephen M Rogers
NPI 1508324468
$4,635.59
in general payments reported to CMS, 2019-2025
29 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,240 · 2022: $1,378 · 2023: $1,230 · 2024: $361 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $680.50 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.21 | 2021-2023 | Jardiance |
| Amgen INC. | $492.21 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $491.33 | 2021-2025 | |
| Pfizer INC. | $425.99 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $272.03 | 2021-2024 | Lifevest |
| Boston Scientific Corporation | $235.04 | 2021-2025 | Watchman Access System |
| Edwards Lifesciences Corporation | $232.03 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $215.53 | 2021-2024 | Airsupra, Brilinta, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $166.05 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $141.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $128.78 | 2022-2023 | Verquvo |
| Atricure, INC. | $94.14 | 2023-2024 | |
| Daiichi Sankyo INC. | $75.73 | 2021-2023 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $47.10 | 2023 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $46.94 | 2024 | Impella |
| Philips North America LLC | $43.37 | 2022-2024 | (Ck7) Extended Holter |
| Vital Connect, INC | $39.84 | 2024 | Vitalpatch Rtm |
| Abbott Laboratories | $37.11 | 2024 | Cardiomems |
| Cvrx, INC. | $31.17 | 2022-2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $26.10 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.95 | 2021-2022 | |
| Medtronic, INC. | $19.74 | 2021 | |
| Impulse Dynamics (USA) INC. | $19.13 | 2024 | Optimizer |
| Amarin Pharma, INC. | $15.86 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Terumo Medical Corporation | $13.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.53 | 2022 | |
| Chiesi USA, INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.